Jones Financial Companies Lllp Boosts Stake in Haleon PLC Sponsored ADR $HLN

Jones Financial Companies Lllp grew its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 16.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 355,851 shares of the company’s stock after acquiring an additional 49,560 shares during the period. Jones Financial Companies Lllp’s holdings in Haleon were worth $3,139,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of HLN. Bank of America Corp DE grew its stake in Haleon by 116.7% during the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after purchasing an additional 6,669,923 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Haleon by 15.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,776,686 shares of the company’s stock valued at $91,014,000 after purchasing an additional 1,174,813 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Haleon by 6.5% during the 2nd quarter. Envestnet Asset Management Inc. now owns 7,857,196 shares of the company’s stock valued at $81,479,000 after buying an additional 476,823 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Haleon by 3,031.5% during the second quarter. Acadian Asset Management LLC now owns 5,384,661 shares of the company’s stock worth $55,813,000 after buying an additional 5,212,711 shares in the last quarter. Finally, Raymond James Financial Inc. grew its position in shares of Haleon by 0.7% during the second quarter. Raymond James Financial Inc. now owns 4,315,180 shares of the company’s stock worth $44,748,000 after buying an additional 29,287 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on HLN shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research note on Tuesday, January 20th. HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft cut Haleon from a “hold” rating to a “sell” rating in a research note on Monday, January 12th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.33.

Haleon Price Performance

HLN opened at $10.98 on Friday. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. The company’s 50-day moving average price is $10.03 and its 200 day moving average price is $9.66. Haleon PLC Sponsored ADR has a fifty-two week low of $8.71 and a fifty-two week high of $11.42. The firm has a market cap of $48.90 billion, a price-to-earnings ratio of 28.15 and a beta of 0.19.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.